Maze Therapeutics (MAZE) Cash from Investing Activities (2024 - 2026)

Maze Therapeutics has disclosed Cash from Investing Activities across 3 years of filings, most recently posting $6.3 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $6.3 million, up 2198.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$164.4 million (down 13986.38% YoY), and the FY2025 annual result was -$171.0 million, down 14805.14% from the prior year.
• Cash from Investing Activities came in at $6.3 million for Q1 2026 at Maze Therapeutics, up from -$103.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $6.3 million in Q1 2026 to a low of -$103.4 million in Q4 2025.
• The 3-year median for Cash from Investing Activities is -$299000.0 (2025), against an average of -$18.4 million.
• Across the five-year window, Cash from Investing Activities tumbled 64834.95% in 2025 and surged 2198.66% in 2026, its largest moves.
• Maze Therapeutics' Cash from Investing Activities stood at -$605000.0 in 2024, then sank by 16988.76% to -$103.4 million in 2025, then jumped by 106.07% to $6.3 million in 2026.
• The last three Cash from Investing Activities figures came in at $6.3 million (Q1 2026), -$103.4 million (Q4 2025), and -$66.9 million (Q3 2025), per Business Quant data.